The NSAID roller coaster: more about rofecoxib

This publication has 25 references indexed in Scilit:

• The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland
  British Journal of Clinical Pharmacology, 2006
• Non‐selective nonsteroidal anti‐inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime?
  British Journal of Clinical Pharmacology, 2006
• Cyclooxygenase‐2 inhibitors and coronary occlusion – exploring dose–response relationships
  British Journal of Clinical Pharmacology, 2006
• Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects
  British Journal of Clinical Pharmacology, 2006
• Prostaglandins, bioassay and inflammation
  British Journal of Pharmacology, 2006
• Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
  New England Journal of Medicine, 2005
• Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
  New England Journal of Medicine, 2005
• Rofecoxib (Vioxx) voluntarily withdrawn from market
  CMAJ : Canadian Medical Association Journal, 2004
• COX-2 inhibitors
  The Lancet, 1999
• Inhibition of Prostaglandin Synthetase in Brain explains the Anti-pyretic Activity of Paracetamol (4-Acetamidophenol)
  Nature, 1972